MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$6,453,685
EPS
-$0.28
Unit: Dollar
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Deemed dividend
-
932,246
-
0
Tax benefit
-
-
-
0
Administration expenses (including noncash compensation expense of 11,581,251 and 52,853,115 for the nine months ended march 31, 2026 and 2025, respectively, and 5,351,136 and 52,838,115 for the three months ended march 31, 2026 and 2025, respectively
6,219,644
3,628,173
4,598,574
3,585,351
Occupancy expenses - related party
10,917
6,600
14,789
6,373
Research and development
169,660
19,961
60,201
53,522
Total operating expenses
6,400,221
3,654,734
4,673,564
3,645,246
Loss from operations
-6,400,221
-3,654,734
-4,673,564
-3,645,246
Interest expense
38,270
58,955
305,649
254,542
Interest income
13
37
19
7
Derivative expense
-
-
-
238,584
Change in fair value of derivative liabilities
-18,146
87,728
-19,706
98,963
Change in fair value of warrant liability
-182,517
-593,710
-
-
Other expense
43,000
54,000
-
-
Settlement expense
90,000
-
-
-
Gain (loss) on extinguishment of debt, net
-74,235
14,317
195,861
-31,000
Foreign currency transaction gain (loss)
35,006
-19,497
-34,699
-1,059
Total other income (expense), net
39,885
563,340
-164,174
-426,215
Loss before taxes
-6,360,336
-3,091,394
-4,837,738
-4,071,461
Net loss
-6,360,336
-3,091,394
-4,837,738
-4,071,461
Net loss
-6,360,336
-4,023,640
-
-4,071,461
Unrealized foreign currency translation loss (gain)
-93,349
-7,846
17,044
-145,640
Total other comprehensive income (gain)
-93,349
-7,846
17,044
-145,640
Total comprehensive loss
-6,453,685
-4,031,486
-4,820,694
-4,217,101
Basic EPS
-0.28
-0.3
-0.39
-1.063
Diluted EPS
-0.28
-0.3
-0.39
-1.063
Basic Average Shares
22,427,486
13,360,358
12,331,526
3,968,176*
Diluted Average Shares
22,427,486
13,360,358
12,331,526
3,968,176*
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Total comprehensiveloss-$6,453,685 (88.07%↑ Y/Y)Net loss-$6,360,336 (88.24%↑ Y/Y)Total othercomprehensive income (gain)-$93,349 (-241.80%↓ Y/Y)Net loss-$6,360,336 (88.24%↑ Y/Y)Unrealized foreigncurrency translation...-$93,349 (-241.80%↓ Y/Y)Change in fair value ofwarrant liability-$182,517 Other expense$43,000 Foreign currencytransaction gain (loss)$35,006 (380.36%↑ Y/Y)Interest income$13 (1200.00%↑ Y/Y)Loss before taxes-$6,360,336 (88.24%↑ Y/Y)Total other income(expense), net$39,885 (104.25%↑ Y/Y)Settlement expense$90,000 Gain (loss) onextinguishment of debt, net-$74,235 (90.83%↑ Y/Y)Interest expense$38,270 (-63.22%↓ Y/Y)Change in fair value ofderivative liabilities-$18,146 (-138.51%↓ Y/Y)Loss from operations-$6,400,221 (87.95%↑ Y/Y)Total operatingexpenses$6,400,221 (-87.95%↓ Y/Y)Administration expenses(including noncash...$6,219,644 (-88.28%↓ Y/Y)Research and development$169,660 (213.62%↑ Y/Y)Occupancy expenses -related party$10,917 (68.76%↑ Y/Y)

Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma, Inc. (PPCB)